136 related articles for article (PubMed ID: 34774129)
1. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
Zacharchenko T; Kalverda AP; Wright SC
Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
[TBL] [Abstract][Full Text] [Related]
2. Backbone resonance assignment of the BCL6-BTB/POZ domain.
Lin LY; Evans SE; Fairall L; Schwabe JWR; Wagner SD; Muskett FW
Biomol NMR Assign; 2018 Apr; 12(1):47-50. PubMed ID: 28929458
[TBL] [Abstract][Full Text] [Related]
3. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
[TBL] [Abstract][Full Text] [Related]
4. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
5. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract][Full Text] [Related]
6. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
[TBL] [Abstract][Full Text] [Related]
7. A peptide aptamer to antagonize BCL-6 function.
Chattopadhyay A; Tate SA; Beswick RW; Wagner SD; Ko Ferrigno P
Oncogene; 2006 Apr; 25(15):2223-33. PubMed ID: 16331266
[TBL] [Abstract][Full Text] [Related]
8. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
9. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
[TBL] [Abstract][Full Text] [Related]
12. GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.
Pearce AC; Bamford MJ; Barber R; Bridges A; Convery MA; Demetriou C; Evans S; Gobbetti T; Hirst DJ; Holmes DS; Hutchinson JP; Jayne S; Lezina L; McCabe MT; Messenger C; Morley J; Musso MC; Scott-Stevens P; Manso AS; Schofield J; Slocombe T; Somers D; Walker AL; Wyce A; Zhang XP; Wagner SD
J Biol Chem; 2021 Aug; 297(2):100928. PubMed ID: 34274316
[TBL] [Abstract][Full Text] [Related]
13. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: T follicular helper cell differentiation is defective in the absence of Bcl6 BTB repressor domain function.
Nance JP; Bélanger S; Johnston RJ; Takemori T; Crotty S
J Immunol; 2015 Jun; 194(12):5599-603. PubMed ID: 25957170
[TBL] [Abstract][Full Text] [Related]
15. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
16. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
17. The NCoR Co-repressor Interacts with the Kaiso Transcription Factor through a Mechanism Different from That of BCL6 Interaction.
Balagurov KI; Georgiev PG; Bonchuk AN
Dokl Biochem Biophys; 2022 Dec; 507(1):326-329. PubMed ID: 36786995
[TBL] [Abstract][Full Text] [Related]
18. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
[TBL] [Abstract][Full Text] [Related]
19. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
[TBL] [Abstract][Full Text] [Related]
20. BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27.
He J; Wu M; Xiong L; Gong Y; Yu R; Peng W; Li L; Li L; Tian S; Wang Y; Tao Q; Xiang T
Clin Epigenetics; 2020 Jun; 12(1):82. PubMed ID: 32517789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
